clinical trial · NCT07869836
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
SystImmune Inc.·phase3·recruiting·n = 520
Urothelial CancerMetastatic Urothelial CancerBladder CancerBladder Cancer (BC)Bladder (Urothelial, Transitional Cell) CancerBladder (Urothelial, Transitional Cell) Cancer Metastatic or UnresectableBladder CaBladder Cancer RecurrentT-Bren, Dose level 1T-bren, Dose level 2Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin)
brief summary
The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.
started
Nov 1, 2026
primary completion
Dec 1, 2028
completion
Dec 1, 2029
last updated
Nov 18, 2026
detailed description
This study is a Global Phase 3, randomized, open-label, multicenter study of T-bren for the treatment of metastatic UC. This study will assess the efficacy and safety of T-bren versus PBC in adult participants with HER2-expressing UC after progression on anti-PD-(L)1-based therapy.
official title
A Phase 3 Open-Label, Randomized Controlled Trial of T-bren (BL M07D1) vs. Platinum-based Chemotherapy in Patients With HER2 Expressing Metastatic Urothelial Cancer With Disease Progression on or After Anti-PD-(L)1-based Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol